Where heart care meets heart science.

Tassos Gianakakos and Jay Edelberg — colleagues from MyoKardia — founded Prolaio as a cardiovascular clinical intelligence company, built on continuous, real-world heart data.

Prolaio acquired technology built on algorithms originally developed to detect early failure signals in jet engines and nuclear power plants. That same predictive science was later adapted for human physiology, evolving into a digital biomarker platform that Prolaio has since grown into its clinical intelligence engine.

Kardigan acquired Prolaio, connecting a cardiovascular drug-development pipeline with one of the largest curated cardiovascular datasets in the industry. Prolaio continues to be offered industry-wide, putting its intelligence engine to work across Kardigan’s three pivotal drug candidate programs.

Prolaio launches the OCORO Heart Study — a national, all-remote observational study sponsored by Prolaio. Using wearable sensors and connected at-home devices, OCORO enrolls U.S. adults living with cardiovascular conditions to capture how heart disease behaves in everyday life and help inform more personalized care.

The FDA clears the prolaio eVO2peak Module — a software-only deep-learning model that estimates peak oxygen consumption from single-lead ECG and triaxial accelerometry. CPET-grade fitness, no exercise protocol required.

Tassos and Jay built both Kardigan and Prolaio with a vision to eventually bring them together — enabling truly personalized cardiovascular therapies targeted to an individual’s disease.